Table 4.
Frequencies and response rates of chemotherapy regimens initially used after ovarian metastasis diagnosis
| Variable | Arm A1a) |
Arm A2 |
Arm B1 |
Arm B2 |
Total |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | RR (%)b) | No. | RR (%) | No. | RR (%) | No. | RR (%) | No. | RR (%) | |
| Platinumc) | 8 | 25 | 1 | 0 | 21 | 14 | 13 | 46 | 43 | 26 |
| Irinotecand) | 0 | 0 | 0 | 0 | 4 | 25 | 4 | 25 | 8 | 25 |
| Taxanee) | 4 | 0 | 2 | 0 | 17 | 18 | 3 | 0 | 26 | 12 |
| Total | 12 | 17 | 3 | 0 | 42 | 17 | 20 | 35 | 77 | 21 |
a)
Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus chemotherapy; arm B, chemotherapy alone,
b)
RR, response rate (comlete response or partial response patients/total patients),
c)
Cisplatin+TS-1, cisplatin+capecitabine (XP), cisplatin+5-fluorouracil (5-FU) (FP), oxaliplatin+capecitabine (XELOX), oxaliplatin+5-FU/leucovorin (LV) (FOLFOX), oxaliplatin+TS-1 (SOX),
d)
Irinotecan mono, irinotecan+TS-1, irinotecan+5-FU/LV (FOLFIRI),
e)
Paclitaxel mono, paclitaxel+5-FU/LV, paclitaxel+TS-1, docetaxel mono, docetaxel+5-FU/LV, docetaxel+TS-1, docetaxel+capecitabine.